Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 27;14:11795476211036322. doi: 10.1177/11795476211036322

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 4. — Clinical course of the patient with anti-MDA5 antibody-positive DM-associated RP-ILD (Case 2). The titer of anti-MDA5 antibody (black circle), serum ferritin level (white circle), and serum KL-6 level (black triangle) are shown. The patient was treated with methylprednisolone pulse therapy (mPSL), prednisolone (PSL), tacrolimus (TAC), intravenous administration of cyclophosphamide (IVCY), and rituximab (RTX). Plasma exchange (PE) 3 times a week was initiated in early February, and a total of 31 PE sessions were performed.